Can an antidepressant also fight chemo nausea? new study tests mirtazapine in brain cancer patients
NCT ID NCT03935685
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 pilot study is testing whether mirtazapine, an antidepressant, can help with depression, nausea, vomiting, and weight loss in people with high-grade glioma who are starting temozolomide chemotherapy. The study enrolled 120 adults with newly diagnosed glioma. Researchers will track changes in depression scores, nausea/vomiting levels, weight, and side effects over eight weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirtazapine (Remeron)
- What this could lead to
- If it works, this could point toward a way to manage both depression and nausea in brain cancer patients, improving their quality of life during chemotherapy.
- What could go wrong
- This is a small, early-phase pilot study with no placebo group, so results may not be definitive. Mirtazapine can cause drowsiness and other side effects, and it may not help everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA OF BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.